A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Conclusions The candidate TB vaccine, MVA85A has been safely administered to over 100 healthy adults in the UK. Intradermal vaccination with MVA85A induced a transient, superficial reaction local to the injection site and mild short-lived viral symptoms. The local and systemic AE profile of MVA85A vaccination was comparable to published data of other intradermal vaccines and live viral vaccines respectively. Local reaction sizes and body temperature measurements did not correlate with the adaptive cellular immune response to MVA85A.
Source: Trials in Vaccinology - Category: Infectious Diseases Source Type: research
More News: African Health | Child Development | Children | Clinical Trials | Headache | Infectious Diseases | Legislation | Migraine | Tuberculosis | Tuberculosis (BCG) Vaccine | Vaccines | Yellow Fever | Yellow Fever Vaccination